Monte Rosa Therapeutics (GLUE) Accumulated Expenses (2023 - 2025)
Historic Accumulated Expenses for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q1 2025 value amounting to $8.0 million.
- Monte Rosa Therapeutics' Accumulated Expenses rose 12675.9% to $8.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.0 million, marking a year-over-year increase of 12675.9%. This contributed to the annual value of $8.2 million for FY2024, which is 825.76% up from last year.
- As of Q1 2025, Monte Rosa Therapeutics' Accumulated Expenses stood at $8.0 million, which was up 12675.9% from $8.2 million recorded in Q4 2024.
- In the past 5 years, Monte Rosa Therapeutics' Accumulated Expenses ranged from a high of $8.2 million in Q4 2024 and a low of $3.2 million during Q1 2023
- For the 3-year period, Monte Rosa Therapeutics' Accumulated Expenses averaged around $6.0 million, with its median value being $6.1 million (2023).
- Per our database at Business Quant, Monte Rosa Therapeutics' Accumulated Expenses skyrocketed by 825.76% in 2024 and then skyrocketed by 12675.9% in 2025.
- Monte Rosa Therapeutics' Accumulated Expenses (Quarter) stood at $7.6 million in 2023, then increased by 8.26% to $8.2 million in 2024, then fell by 2.37% to $8.0 million in 2025.
- Its last three reported values are $8.0 million in Q1 2025, $8.2 million for Q4 2024, and $7.1 million during Q3 2024.